Conduct Phase III clinical trial: CDSCO to Zydus Healthcare over FDC Empagliflozin plus Sitagliptin Dr. Divya Colin12 Nov 2023 4:00 PM ISTNew Delhi: In response to the proposal presented by the drug major Zydus Healthcare, the Subject Expert Committee ( SEC) functional under the Central...
Aldosterone synthase inhibitor shows promise in CKD trial: Boehringer Ingelheim Ruchika Sharma5 Nov 2023 2:30 PM ISTGermany: Boehringer Ingelheim has announced promising 14-week Phase II data for BI 690517, a novel selective aldosterone synthase inhibitor...
Dr Reddy's Gets CDSCO Panel Nod to Study Antidiabetic FDC Empagliflozin, Sitagliptin, Metformin tablet Dr. Divya Colin20 Oct 2023 6:00 PM ISTNew Delhi: The drug major Dr Reddy's Laboratories has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard...
Empagliflozin lowers high BP and hyperuricemia in patients with type 2 diabetes Medha Baranwal18 Oct 2023 11:15 AM ISTChina: Treatment with the SGLT2 inhibitor Empagliflozin is effective in controlling hypertension and hyperuricemia in diabetes patients, a systematic...
Can semaglutide and empagliflozin combo lower albuminuria in patients with type 2 diabetes? Medha Baranwal30 Sept 2023 11:45 AM ISTDenmark: A randomized and placebo-controlled study investigated the albuminuria-lowering effect of semaglutide addition on top of empagliflozin in...
Medical Bulletin 29/September/2023 Isra Zaman29 Sept 2023 3:15 PM ISTHere are the top medical news of the day:FDA approves Bosutinib for pediatric Chronic Myelogenous Leukemia patientsOn September 26, 2023, the Food and...
FDA approves Empagliflozin for reducing kidney disease progression in CKD patients Isra Zaman29 Sept 2023 9:45 AM ISTThe U.S. Food and Drug Administration (FDA) has granted approval for empagliflozin 10 mg tablets to reduce the risk of sustained decline in estimated...
Eli Lilly-Boehringer Ingelheim Jardiance gets USFDA approval for adults with chronic kidney disease Ruchika Sharma23 Sept 2023 12:30 PM ISTRidgefield: Eli Lilly and Company and Boehringer Ingelheim have announced that the U.S. Food and Drug Administration (FDA) has approved Jardiance...
FDA Approves Empagliflozin for CKD treatment, regardless of diabetes status Dr. Kamal Kant Kohli23 Sept 2023 10:45 AM ISTThe US Food and Drug Administration has approved another SGLT2 Inhibitor Empagliflozin for treatment of CKD regardless of diabetes status.Jardiance®...
Empagliflozin reduces HF hospitalization and CV death regardless of baseline diuretic doses Dr. Shravani Dali18 Sept 2023 12:00 PM ISTEmpagliflozin reduces HF hospitalization and CV death regardless of baseline diuretic doses suggests a new study published in the JACC: Heart...
Synokem Gets CDSCO Panel Nod to Study Antidiabetic FDC Drug Sitagliptin plus Empagliflozin Dr. Divya Colin3 Sept 2023 6:00 PM ISTNew Delhi: The drug major Synokem Pharmaceuticals has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard...
Eli Lilly- Boehringer Ingelheim Jardiance gets European Commission nod to treat adults with CKD Ruchika Sharma26 July 2023 4:30 PM ISTIngelheim: The European Commission (EC) has approved Jardiance (empagliflozin) for the treatment of adults with chronic kidney disease (CKD),...
